-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMC-002 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMC-002...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Danburstotug in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Danburstotug in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Danburstotug in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Crenolanib Besylate in Gastrointestinal Stromal Tumor (GIST)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Crenolanib Besylate in Gastrointestinal Stromal Tumor (GIST) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Crenolanib Besylate in Gastrointestinal Stromal Tumor (GIST) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Neuroblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nivolumab in Neuroblastoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Neuroblastoma Drug Details: Nivolumab (Opdivo, Opdyta) is a human IgG4...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Danburstotug in T-Cell Lymphomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Danburstotug in T-Cell Lymphomas Drug Details: STIA-1015 is under development for the treatment of solid...
-
Product Insights
NewNatural Killer Cell Lymphomas – Drugs In Development, 2024
Empower your strategies with our Natural Killer Cell Lymphomas – Drugs In Development, 2024 report and make more profitable business decisions. Natural killer (NK) cell lymphomas are a rare and aggressive type of lymphoma arising from a subset of white blood cells called natural killer cells, which are part of the body's immune system. These lymphomas can affect various organs and tissues in the body. NK cell lymphomas are categorized into two main types. Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is...
-
Product Insights
NewGallbladder Cancer – Drugs In Development, 2024
Empower your strategies with our Gallbladder Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Gallbladder cancer symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine, and weight loss. Risk factors include overweight, age, family history, gallstones, gender, and choledochal cysts. Treatment includes surgery, chemotherapy, and radiation therapy. The Gallbladder Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Gallbladder Cancer, complete with...